Can a new shot stop sickle cell pain attacks?

NCT ID NCT05075824

Completed Prevention Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 26 times

Summary

This study tested a drug called crovalimab to see if it can prevent vaso-occlusive episodes (painful blockages in blood vessels) in people with sickle cell disease. 95 participants received either crovalimab or a placebo alongside their usual treatments. The goal was to reduce the number of pain crises that require medical care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Adana Acibadem Hospital; Pediatric Hematology

Adana, 01130, Turkey (Türkiye)
Amsterdam UMC Location VUMC

Amsterdam, 1081 HV, Netherlands
Azienda Ospedaliera di Verona-Policlinico G.B. Rossi

Verona, Veneto, 37134, Italy
Beneficencia Portuguesa de Sao Paulo

São Paulo, São Paulo, 01323-900, Brazil
CHU Henri Mondor

Créteil, 64010, France
Central Middlesex Hospital

London, NW10 7NS, United Kingdom
Charlotte Maxeke Johannesburg Hospital

Johannesburg, 2193, South Africa
Children's Hospital of Michigan

Detroit, Michigan, 48201, United States
Cukurova University Medical Faculty Balcali Hospital

Adana, 1330, Turkey (Türkiye)
East Carolina University

Greenville, North Carolina, 27834, United States
Gertrude's Children Hospital

Nairobi, Kenya
HEMORIO

Rio de Janeiro, 20211-030, Brazil
Hammersmith Hospital

London, W12 0HS, United Kingdom
Hopital Nini

Tripoli, Lebanon
Hospital General Univ. Gregorio Maranon

Madrid, 28009, Spain
Hospital Samaritano

São Paulo, 01232-010, Brazil
Hospital Sao Rafael - HSR

Salvador, Estado de Bahia, 41253-190, Brazil
Hospital Universitario Miguel Servet

Zaragoza, 50009, Spain
Hospital das Clinicas - UFRGS

Porto Alegre, Rio Grande do Sul, Brazil
Hospital das Clínicas Faculdades Médicas de Ribeirão Preto

Ribeirão Preto, São Paulo, 14051-140, Brazil
Hospital de Base de Sao Jose do Rio Preto

São José do Rio Preto, São Paulo, 15090-000, Brazil
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
International Cancer Institute (ICI)

Eldoret, 30100, Kenya
Mersin Universitesi Tip Fakultesi Hastanesi

Mersin, 33343, Turkey (Türkiye)
Mississippi Center for Advanced Medicine

Madison, Mississippi, 39110, United States
UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu

Botucatu, São Paulo, 18618-970, Brazil
Università degli Studi della Campania Luigi Vanvitelli

Naples, Campania, 80138, Italy

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

crovalimab

What this could lead to

If it works, crovalimab could become a new option to help prevent painful sickle cell crises, reducing hospital visits and improving daily life.

What could go wrong

This is a small, early-phase (Phase 2) study, so results may not confirm benefit. The drug also carries infection risks because it affects the immune system.

Conditions

The condition(s) this trial relates to.

sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SICKLE CELL DISEASE